

Sarcoidosis Mimicking Multiple Myeloma.

Gabriela Firak DO

Lehigh Valley Health Network, Gabriela.Firak@lvhn.org

Sehris Khawaja DO

Lehigh Valley Health Network, Sehris.Khawaja@lvhn.org

Follow this and additional works at: <https://scholarlyworks.lvhn.org/medicine>



Part of the [Internal Medicine Commons](#), and the [Medical Sciences Commons](#)

Let us know how access to this document benefits you

Published In/Presented At

Firak, G. Khawaja, S. (2017, March). *Sarcoidosis Mimicking Multiple Myeloma*. Poster Presented at: American College of Physicians, San Diego

This Poster is brought to you for free and open access by LVHN Scholarly Works. It has been accepted for inclusion in LVHN Scholarly Works by an authorized administrator. For more information, please contact LibraryServices@lvhn.org.

Sarcoidosis Mimicking Multiple Myeloma

Gabriela Firak DO and Sehris Khawaja DO
Lehigh Valley Health Network, Allentown, Pennsylvania

BACKGROUND

- Sarcoidosis is a systemic disease of unknown etiology characterized by non-caseating granuloma formation affecting primarily young individuals aged 20-39.⁴
- In over 90 percent of the cases sarcoidosis targets the lungs or the related lymph nodes but it can affect any organ system.⁴

CASE PRESENTATION

- A 70-year-old Caucasian female presented to the emergency department with symptoms of confusion and low back pain. She was found to have an elevated calcium level of 14 mg/dL, creatinine of 3.8 mg/dL with a baseline of 1.3 mg/dL, and a hemoglobin of 10 g/dL with a baseline of 12 g/dL.
- X-ray imaging of the lumbar spine was concerning for a compression fracture with osteolytic changes.
- She was treated with intravenous hydration and calcitonin with correction of her renal and electrolyte abnormalities.
- Her presentation raised concern for multiple myeloma and work up was initiated.
- Surprisingly, the bone marrow biopsy demonstrated granulomatous inflammation.
- In addition, laboratory data revealed SPEP/UPEP negative for monoclonal gammopathy, as well as elevated 1,25-dihydroxyvitamin D and angiotensin converting enzyme (ACE) levels.
- A skeletal survey was performed for completion and was unremarkable for additional bony abnormalities.
- Additional laboratory data performed in context of hypercalcemia work up was also unrevealing as seen in Table 2.
- Inconsistent with the diagnosis, CT of the chest was negative for parenchymal or lymph node involvement of the pulmonary system.
- Patient also displayed potential cardiac manifestations of her disease given history of conduction abnormalities requiring a pacemaker as well as a diagnosis of diastolic dysfunction.
- This information supported the diagnosis of sarcoidosis.

Table 2.

Parathyroid Hormone	6.2 pg/mL
Parathyroid Related Peptide	3.4 pmL/L
Angiotensin Converting Enzyme	89 U/L
1,25-OH	143/pg/mL
25-OH	25 ng/mL
Alkaline Phosphatase	69 U/L




Figure 1. CT chest without evidence of pulmonary sarcoidosis




Figure 2. Granulomatous Inflammation

DISCUSSION

- Isolated extrapulmonary manifestations of sarcoidosis are rare and present in less than 10 percent of reported cases.¹
- Bone marrow involvement has only been described in less than 5 percent of cases.³
- This is potentially due to a low number of bone biopsies performed and could underrepresent the true incidence of bone marrow sarcoidosis.³
- Sarcoid can present as sclerotic or lytic lesions on radiographic data.⁶
- Hematologic abnormalities can be seen in up to 30 percent of cases.⁵
- Steroids are first line therapy for any manifestation of sarcoidosis.²
- While there is a broad differential for granulomatous lesions the clinical picture of the patient presented is less likely a result of other infectious, vasculitic, neoplastic, or chemical/environmental etiologies.

References:

1. Alizadeh, Leila, et al. "Pancreatic Sarcoidosis: Review Article." *Journal of the Pancreas*. 08 Nov. 2016.
2. Al-Kofahi, Khalid, Peter Korsten, and Christian Ascoli. "Management of Extrapulmonary Sarcoidosis: Challenges and Solutions." *Therapeutics and Clinical Risk Management*. Dove Medical Press Ltd., 23 Dec. 2016.
3. Baughman RP, Teirstein AS, Judson MA, Rossman MD, et al. Case Control Etiologic Study of Sarcoidosis (ACCESS) research group: Clinical characteristics of patients in a case control study of sarcoidosis. *Am J Respir Crit Care*. 2001; 164: 1885-1889.
4. Ianuzzi, Michael C., Benjamin A. Rybicki, and Alvin S. Teirstein "Sarcoidosis — NEJM." *New England Journal of Medicine*. 2007.
5. Lower EE, Smith JT, Martelo OJ, Baughman RP. The anemia of sarcoidosis. *Sarcoidosis* 1988;5:51–55.
6. Palmucci, Stefano, Sebastiano Emanuele Torrisi, et al. "Clinical and Radiological Features of Extra-pulmonary Sarcoidosis: A Pictorial Essay." *Insights into Imaging* 7.4 (2016): 571-87.
7. Rao, Deepak A., and Paul F. Dellaripa. "Extrapulmonary Manifestations of Sarcoidosis." *Rheumatic Disease Clinics of North America* 39.2 (2013): 277-97.

FOLLOW-UP

- Patient was discharged on a year long steroid taper without recurrence of hypercalcemia during the course of the year.
- Her hemoglobin increased from 10 g/dL on initial presentation to her baseline of 12 g/dL.

© 2017 Lehigh Valley Health Network

610-402-CARE LVHN.org